2025 · Poster Presentation · Merck · Hepatology
Co-Founder & Chief Clinical Officer
Michael W. Fried, MD, FAASLD
Dr. Fried is Chief Medical Officer and Co-Founder of Target RWE. He is also Professor of Medicine at the University of North Carolina at Chapel Hill and Past-President of the American Association for the Study of Liver Diseases (AASLD). Dr. Fried trained at the State University of New York at Syracuse and the National Institutes of Health, Bethesda, MD, which provided him with the foundation for his 30 years of experience in clinical and translational research. Dr. Fried is co-author of 200+ publications in the field of liver disease and is currently co-chair of the NIH Hepatitis B Research Network. He is co-principal investigator of the HCV-TARGET network which was awarded the FDA Excellence in Regulatory Science Award for contributions to optimizing management for hepatitis C.

Publications
24
Total Publications
2025 · Abstract/Manuscript · UNC
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH
Read more →2025 · Abstract/Manuscript
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
Read more →2025 · Poster Presentation · University of Miami (FL) · Hepatology
Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease
Read more →2023 · Poster Presentation · Cleveland Clinic · Hepatology
A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS
Read more →2023 · Abstract/Manuscript · National University Hospital
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Read more →2023 · Oral Presentation · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation
Read more →2022 · Poster Presentation · Saint Louis University · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH
Read more →2022 · Poster Presentation · Novartis · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks
Read more →2022 · Poster Presentation · University of Chicago · Gastroenterology
The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · Zucker School of Medicine at Hofstra
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
Read more →2021 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Associated with Readmission in the US Following Hospitalization with COVID-19
Read more →2020 · Poster Presentation · University of Miami (FL) · Hepatology
A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes
Read more →2020 · Poster Presentation · Heinrich-Heine University Düsseldorf · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice
Read more →2020 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States
Read more →2019 · Poster Presentation · University of Pennsylvania · Methods/Pharmacoepi
Factors Associated with Readmission Following COVID-19 Hospitalization
Read more →2018 · Poster Presentation · Stanford · Hepatology
Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)
Read more →2018 · Poster Presentation · Stanford · Hepatology